Effects of High-flow Oxygen Therapy and Non-invasive Ventilation on Lung Volumes and on Upper Airway
Launched by UNIVERSITY HOSPITAL, MONTPELLIER · Dec 1, 2022
Trial Information
Current as of February 05, 2025
Recruiting
Keywords
ClinConnect Summary
This clinical trial is looking at two different treatments for patients with respiratory failure, a serious condition where the lungs can't provide enough oxygen to the body. The study specifically compares high-flow nasal cannula oxygen therapy (HFNC), which delivers a higher amount of oxygen through thin tubes that sit in the nose, to non-invasive ventilation (NIV), which uses a mask to help patients breathe. Researchers want to find out if using NIV leads to a bigger increase in lung volume compared to HFNC when patients are critically ill and dealing with low oxygen levels.
To be eligible for the study, participants must be adults aged 18 or older who are experiencing low oxygen levels during their time in the ICU and require oxygen therapy to maintain healthy oxygen levels. They must also have a CT scan ordered by their doctor as part of their medical care. However, certain individuals, like those needing immediate intubation, pregnant women, or those with recent facial injuries, cannot join the study. Participants can expect close monitoring and care while contributing to important research that could improve treatment options for respiratory failure in the future.
Gender
ALL
Eligibility criteria
- Inclusion Criteria:
- • Patient with hypoxemia at any time of ICU stay defined as follow: standard oxygen therapy flow ≥ 3L/min to maintain a pulsed oxygen saturation ≥ 95%
- • Adult (age ≥ 18 years)
- • (2) A CT scan prescribed by the physician in charge of the patient as part of the exploration of the patient's pathology and not as part of a "dedicated" prescription for the study.
- Exclusion Criteria:
- • NIV contraindication (need for immediate endotracheal intubation and mechanical ventilation; hemodynamic instability defined by systolic blood pressure \< 90 mmHg or mean blood pressure \< 65 mmHg, use of vasopressors; Glasgow Coma Scale score of 12 points or less)
- • History of recent facial trauma not compatible with the use of nasal cannulas
- • Pregnancy
- • Refusal of study participation
- • protected person
- • Patient not affiliated to the social security system or not benefiting from such a system
- • Lack of signed informed consent
About University Hospital, Montpellier
The University Hospital of Montpellier is a leading academic medical institution dedicated to advancing healthcare through innovative research and clinical trials. Renowned for its commitment to patient-centered care, the hospital collaborates with multidisciplinary teams to explore cutting-edge treatments and therapies across various medical fields. By integrating clinical practice with education and research, the University Hospital of Montpellier aims to enhance health outcomes and contribute to the scientific community's understanding of complex medical conditions. Its robust infrastructure and expertise make it a pivotal player in the landscape of clinical research.
Contacts
Jennifer Cobb
Immunology at National Institute of Allergy and Infectious Diseases (NIAID)
Locations
Montpellier, Languedoc Roussillon, France
People applied
Timeline
First submit
Trial launched
Trial updated
Estimated completion
Not reported
Discussion 0
Similar Trials